Document is current
Any future updates will be listed below
-
Authors
Billah, Tashrif
Cho, Kang Ik K. https://orcid.org/0000-0001-7135-3848
Borders, Owen
Chung, Yoonho
Ennis, Michaela
Jacobs, Grace R. https://orcid.org/0000-0001-9961-6507
Liebenthal, Einat
Mathalon, Daniel H.
Mohandass, Dheshan https://orcid.org/0009-0002-5150-0542
Nicholas, Spero C.
Pasternak, Ofer
Penzel, Nora https://orcid.org/0000-0003-1624-386X
Eichi, Habiballah Rahimi
Wolff, Phillip
Anticevic, Alan
Laulette, Kristen
Nunez, Angela R.
Tamayo, Zailyn
Buccilli, Kate
Colton, Beau-Luke
Dwyer, Dominic B. https://orcid.org/0000-0003-3949-5867
Hendricks, Larry
Yuen, Hok Pan https://orcid.org/0000-0002-1237-1322
Spark, Jessica
Tod, Sophie
Carrington, Holly
Chen, Justine T.
Coleman, Michael J.
Corcoran, Cheryl M. https://orcid.org/0000-0002-8902-4353
Haidar, Anastasia
John, Omar https://orcid.org/0009-0008-3745-7270
Kelly, Sinead
Marcy, Patricia J.
Matneja, Priya
McGowan, Alessia
Ray, Susan E.
Veale, Simone
Winter-Van Rossum, Inge
Addington, Jean https://orcid.org/0000-0002-8298-0756
Allott, Kelly A. https://orcid.org/0000-0002-0640-4634
Calkins, Monica E.
Clark, Scott R. https://orcid.org/0000-0003-1640-5611
Gur, Ruben C.
Harms, Michael P. https://orcid.org/0000-0001-7945-036X
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Ruparel, Kosha
Stone, William S.
Torous, John https://orcid.org/0000-0002-5362-7937
Yung, Alison R. https://orcid.org/0000-0002-0401-9791
Zoupou, Eirini
Fusar-Poli, Paolo
Mittal, Vijay A. https://orcid.org/0000-0001-9017-5119
Shah, Jai L. https://orcid.org/0000-0002-7549-6990
Wolf, Daniel H. https://orcid.org/0000-0002-9731-8781
Cecchi, Guillermo https://orcid.org/0000-0003-1013-8348
Kapur, Tina
Kubicki, Marek https://orcid.org/0000-0002-3989-8212
Lewandowski, Kathryn Eve https://orcid.org/0000-0003-1477-6187
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
McGorry, Patrick D.
Kahn, René S. https://orcid.org/0000-0001-5909-8004
Kane, John M.
Nelson, Barnaby
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
,
Baker, Justin T.
Bouix, Sylvain https://orcid.org/0000-0003-1326-6054
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U24MH124629, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U01MH124631, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U01MH124639, U24MH124629, U01MH124639, U24MH124629, U24MH124629, U01MH124639, U01MH124631, U01MH124639, U01MH124631, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124631, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U01MH124639, U24MH124629, U24MH124629, U24MH124629, U24MH124629, U01MH124639, U01MH124631, U24MH124629, U01MH124639, U01MH124631, U01MH124639, U24MH124629, U24MH124629, U24MH124629)
Canada Research Chairs (CRC-2022-00183)
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (RGPIN-2023-05443)
- License Information
-
More Information
Article History
Received: 4 September 2024
Accepted: 6 December 2024
First Online: 3 April 2025
Competing interests
: A.A. is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019. D.D. has received honorary funds for one educational seminar for CSL Sequiris. J.K. is consultant to, or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, L.B. Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Teva. He is on the advisory boards of Alkermes, Boehringer-Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, Terran. He receives grant support from Lundbeck, Janssen, Otsuka, Sunovion. He is a shareholder of Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), L.B. Pharmaceuticals, Inc. (private/stock options), North Shore Therapeutics (private/stock), Vanguard Research Group (private/40% owner). P.F.P. has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, Otsuka, outside the current study. P.J.M. has been a consultant for Otsuka and TEVA. R.S.K. has been consulting for Alkermes, Boehringer-Ingelheim. S.W.W. has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonizts. He owns stock in N.W. PharmaTech. J.T. is advisor to Precision Mental Wellness. Research support from Otsuka. K.A. is on the CIAS Advisory Board for Boehringer Ingelheim. Z.T. is a consultant for Manifest Technologies. All other authors declare no Competing Financial or Non-Financial Interests.
